Antibody-based therapeutics are advancing in clinical development at a rapid rate and being approved in record numbers.
To keep our members up to date on recent events, we compile relevant information from news releases and other sources, and send this “Antibody News You Should Know” to our members via email twice per month. We include news about:
- Clinical studies started recently, focusing on the first Phase 1, Phase 2 or Phase 3 study
- Submission of marketing applications
- Marketing approvals
- Financing, collaborations and licensing deals
- Regulatory agency designations granted (e.g., Orphan Drug, PRIME, Breakthrough Therapy, Priority review)
If you are not a Society member, please register to receive Antibody News delivered twice a month by email.
From March 15, 2020 to July 1, 2022, we included in-depth coverage of news related to COVID-19 biologic interventions.
As a service to the community, The Antibody Society offers past “Antibody News You Should Know”, which can be accessed via links below. The PDFs include links to the original source and can be searched by keywords (e.g., SARS-CoV-2, bispecific, antibody-drug conjugate).
2023 Antibody News You Should Know
View PDF of Antibody News from Q1 2023 (Jan-Mar).
2022 Antibody News You Should Know
View PDF of Antibody News from Q4 2022 Oct-Dec).
View PDF of Antibody News from Q3 2022 (Jul-Sep).
View PDF of Antibody News from Q2 2022 (Apr-Jun).
View PDF of Antibody News from Q1 2022 (Jan-Mar).
2021 Antibody News You Should Know
View PDF of Antibody News from Q4 2021 (Oct-Dec).
View PDF of Antibody News from Q3 2021 (Jul-Sep).
View PDF of Antibody News from Q2 2021 (Apr-Jun).
View PDF of Antibody News from Q1 2021 (Jan-Mar).
2020 Antibody News You Should Know
View PDF of Antibody News from H2 2020 (Jul-Dec).
View PDF of Antibody News from Q2 2020 (Apr-Jun).
View PDF of Antibody News from Q1 2020 (Jan-Mar).
2019 Antibody News You Should Know
View PDF of Antibody News from Apr 15-Dec 31, 2019
